Barclays on Centene (CNC): 'Medicaid Update Better Than Feared'
Tweet Send to a Friend
Barclays analyst Andrew Mok reiterated an Equalweight rating and $33.00 price target on Centene (NYSE: CNC).The analyst comments "2025 EPS ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


